Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 278-286, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-928809
ABSTRACT
Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inhibidores de la Angiogénesis
/
Terapia Molecular Dirigida
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Neovascularización Patológica
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS